MedTrace Logo

A Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors

NCT06154343 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2023-12-04

No results posted yet for this study

Summary

This is an open-label, phase I study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of GQ1005 and preliminary anti-tumor efficacy in HER2 expressing or mutated advanced malignant solid tumor subjects.

Conditions

  • HER2 Expressing or Mutated Advanced Malignant Solid Tumors

Interventions

DRUG

GQ1005

an antibody drug conjugate

Sponsors & Collaborators

  • GeneQuantum Healthcare (Suzhou) Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-23
Primary Completion
2024-12-31
Completion
2025-07-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06154343 on ClinicalTrials.gov